Did Avexitide Reduce Hypoglycemic Events by 55%? What the Phase 3 LUCIDITY Results Actually Show
The concise answer
Amylyx Pharmaceuticals reported that avexitide reduced the rate of combined Level 2 and Level 3 hypoglycemic events by 55% relative to placebo during the 16-week, double-blind portion of the Phase 3 LUCIDITY trial. The sponsor said the primary endpoint and all secondary endpoints were met.
That is a meaningful late-stage result, but the wording matters. The announcement described a relative event-rate reduction—not a 55-percentage-point reduction, not a claim that 55% of participants were cured, and not proof that every participant experienced the same benefit. Amylyx has released topline findings; complete numerical results have not yet been posted to ClinicalTrials.gov or published in a peer-reviewed paper.
Avexitide also remains investigational. Amylyx said it plans to submit a New Drug Application to the FDA by the end of 2026, but positive Phase 3 results and FDA designations are not FDA approval.
What is avexitide?
Avexitide, formerly known as exendin (9-39), is an investigational peptide that blocks the glucagon-like peptide-1 receptor. That makes it fundamentally different from the GLP-1 receptor agonists used in approved diabetes and weight-management drugs.
GLP-1 agonists activate the receptor. Avexitide is designed to antagonize, or inhibit, excessive GLP-1 signaling at pancreatic beta cells. Amylyx is studying that mechanism in post-bariatric hypoglycemia, a condition in which an exaggerated response after eating can drive excessive insulin secretion and recurrent low blood glucose.
This agonist-versus-antagonist distinction is easy to lose in online discussion. The presence of “GLP-1” in a compound description does not mean that every GLP-1-related drug has the same mechanism, intended population, or clinical effect. For an example of an investigational GLP-1 agonist-based approach, compare the JD BioWorks review of the zenagamtide Phase 2 trial.
What is post-bariatric hypoglycemia?
Post-bariatric hypoglycemia, often abbreviated PBH, is recurrent low blood glucose that can develop after bariatric surgery. LUCIDITY enrolled adults with PBH following Roux-en-Y gastric bypass.
The condition commonly appears after meals and can include autonomic symptoms as well as neuroglycopenic symptoms caused by inadequate glucose delivery to the brain. Severe episodes may impair cognition or physical function and may require help from another person.
The 2024 Society for Endocrinology guideline describes dietary intervention as central to management and lists several pharmacologic approaches for selected patients. At the time of that guideline, avexitide was appropriately framed as an option within investigational trials—not an approved routine treatment.
How was the Phase 3 LUCIDITY trial designed?
ClinicalTrials.gov record NCT06747468 describes LUCIDITY as a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. Amylyx reported the following design details:
- 78 adults with PBH following Roux-en-Y gastric bypass were enrolled;
- the trial was conducted at 21 U.S. sites;
- participants were randomized in a 3:2 ratio;
- the active group received 90 mg of avexitide subcutaneously once daily;
- the placebo-controlled treatment period lasted 16 weeks; and
- a 32-week open-label extension remained ongoing when the topline results were announced.
The primary endpoint was the composite rate of Level 2 and Level 3 hypoglycemic events through Week 16. Level 2 events involve clinically significant low glucose, while Level 3 events are severe episodes characterized by altered mental or physical status requiring assistance. The trial incorporated self-monitored blood glucose, continuous glucose monitoring, and independent adjudication for severe events.
What did Amylyx report?
In its August 18, 2026 topline announcement, Amylyx reported a 55% reduction in the composite rate of Level 2 and Level 3 hypoglycemic events compared with placebo, with a reported p-value of 0.000003.
The company also said LUCIDITY met all secondary endpoints, including reductions in:
- Level 2 events measured by self-monitoring of blood glucose;
- Level 2 events measured by continuous glucose monitoring; and
- independently adjudicated Level 3 events.
Those findings are sponsor-reported topline results. The news release did not provide the complete event counts, group-specific event rates, confidence intervals, participant-level response distribution, missing-data analysis, or full statistical tables needed for an independent assessment of effect size.
What does “55% reduction” mean?
The reported 55% figure is a relative reduction in event rate versus placebo. It should not be translated into any of the following claims:
- 55% of participants stopped having hypoglycemia;
- each participant experienced 55% fewer events;
- the absolute risk fell by 55 percentage points;
- avexitide prevented every severe event; or
- treatment is 55% “effective.”
For illustration only, if a placebo group experienced an average event rate of 10 under a defined analysis, a 55% relative rate reduction would correspond to an average rate of 4.5 under the same definition. That example is arithmetic, not LUCIDITY data. Amylyx did not disclose the underlying group-specific rates in the topline release.
Without those raw rates, it is not possible to calculate an absolute event-rate difference, a participant-level probability of benefit, or a number needed to treat from the announcement alone.
What safety information was reported?
Amylyx said avexitide was generally well tolerated during the double-blind period. According to the company:
- most adverse events were mild to moderate;
- no serious adverse events were considered related to avexitide; and
- the most common adverse events were diarrhea, injection-site erythema, and injection-site bruising.
The sponsor also reported no change in body weight in either group over 16 weeks. That point helps prevent another misleading inference: LUCIDITY was not a weight-loss trial, and avexitide is a GLP-1 receptor antagonist rather than a GLP-1 weight-management drug.
The safety description remains preliminary. A 78-participant trial over 16 controlled weeks cannot reliably characterize uncommon harms, multiyear safety, or use in populations that were not enrolled. Complete adverse-event tables, discontinuation data, exposure information, and the ongoing extension will provide more context.
How strong is the evidence?
LUCIDITY has important design strengths: randomization, placebo control, double blinding, a prespecified Phase 3 endpoint, and independent adjudication of Level 3 events. It also follows earlier controlled human research.
For example, the peer-reviewed Phase 2 PREVENT trial evaluated 18 women with PBH in a randomized crossover design. That study reported improvements in glucose nadir, insulin peak, and several hypoglycemia measures over short treatment periods. LUCIDITY is larger and later-stage, but it is still a relatively small and narrowly defined trial.
The central evidence limitation today is not whether Amylyx announced a positive result—it did. The limitation is that the full Phase 3 dataset is not yet public. ClinicalTrials.gov currently lists no posted results, and Amylyx said it plans to present the data at a future medical meeting. Until complete results are available, precise conclusions should remain tied to the sponsor’s stated endpoints and wording.
Is avexitide FDA approved?
No. Avexitide is investigational.
Amylyx states that FDA has granted avexitide Breakthrough Therapy Designation for PBH and Orphan Drug Designation for hyperinsulinemic hypoglycemia. These designations can support development and regulatory interaction, but neither is marketing approval.
The company said it plans to submit an NDA by the end of 2026. A planned submission is not a submitted application, and a submitted application is not an approval. FDA would still need to accept and review the application and determine whether the evidence supports approval for a specific indication and labeling.
What does the trial not establish?
The topline result does not establish:
- effectiveness in people whose hypoglycemia is unrelated to Roux-en-Y gastric bypass;
- benefit after sleeve gastrectomy or in congenital hyperinsulinism;
- long-term safety or durability beyond the available follow-up;
- equivalence of any independently supplied material to the clinical-trial product;
- a personal dosing protocol;
- weight-loss benefit; or
- FDA approval.
It also should not be compared directly with headline percentages from GLP-1 agonist obesity trials. LUCIDITY studied a different mechanism, population, outcome, duration, and clinical problem.
What should researchers watch next?
The most informative next steps will be:
- presentation of complete LUCIDITY results at a medical meeting;
- posting of results to ClinicalTrials.gov;
- a peer-reviewed Phase 3 publication;
- full adverse-event, discontinuation, and subgroup data;
- outcomes from the 32-week open-label extension; and
- confirmation of any NDA submission and subsequent FDA review milestones.
This is a different evidence stage from a trial registration with no outcomes. For help distinguishing a registered study from reported evidence, see the JD BioWorks explanation of the MOTS-c Phase 2 trial record.
Frequently asked questions
Is avexitide a GLP-1 agonist?
No. Avexitide is a GLP-1 receptor antagonist. It is designed to inhibit excessive GLP-1-driven insulin secretion rather than activate the receptor.
Are avexitide and exendin (9-39) the same compound?
Avexitide is the name used for the investigational exendin (9-39) peptide studied in the cited PBH trials.
Did LUCIDITY show 55% of participants were cured?
No. Amylyx reported a 55% relative reduction in the composite event rate versus placebo. The announcement did not report a 55% cure rate or say that every participant experienced the same change.
Were the Phase 3 results peer reviewed?
Not yet. Amylyx announced topline results on August 18, 2026. Complete Phase 3 results have not yet been posted to ClinicalTrials.gov or published in a peer-reviewed paper.
Does Breakthrough Therapy Designation mean FDA approval?
No. It is a development and review designation, not permission to market a drug. Avexitide remains investigational unless and until FDA approves a specific application.
The bottom line
The Phase 3 LUCIDITY result is an important signal: in a randomized 78-participant trial, Amylyx reported a 55% relative reduction in the rate of combined Level 2 and Level 3 hypoglycemic events over 16 weeks, and said all secondary endpoints were met.
The responsible interpretation is encouraging but bounded. The result is sponsor-reported topline evidence from a specific PBH population. It is not a 55% cure rate, does not establish long-term safety, and does not make avexitide FDA approved. Full results will be necessary to assess absolute event rates, confidence intervals, participant-level outcomes, missing data, and longer-term safety.
Explore the JD BioWorks Research Library for source-linked explanations of peptide trials, regulatory developments, and evidence limitations.
Sources
- Amylyx Pharmaceuticals. Positive topline results from the Phase 3 LUCIDITY trial of avexitide. August 18, 2026.
- ClinicalTrials.gov. NCT06747468: Avexitide for Treatment of Post-Bariatric Hypoglycemia. Record last updated August 24, 2026.
- Craig CM, et al. PREVENT: A randomized, placebo-controlled crossover trial of avexitide for treatment of postbariatric hypoglycemia. Journal of Clinical Endocrinology & Metabolism. 2021;106(8):e3235-e3248.
- Tan M, et al. Safety, efficacy and pharmacokinetics of repeat subcutaneous dosing of avexitide for treatment of post-bariatric hypoglycaemia. Diabetes, Obesity and Metabolism. 2020;22(8):1406-1416.
- Society for Endocrinology. Guidelines for the diagnosis and management of post-bariatric hypoglycaemia. Endocrine Connections. 2024;13(5):e230285.
Medical and research-use disclaimer: This article summarizes public clinical-trial information for educational purposes. It is not medical advice, treatment guidance, a recommendation to use avexitide, or a substitute for care from a qualified clinician. Avexitide is investigational. JD BioWorks materials are intended for qualified laboratory research only and are not for human or veterinary use.